News about rnatics 8.10.24 2024 Nobel prize in Medicine awarded to microRNA 2024 Nobel prize in Medicine awarded to microRNA - the target of RNATICS’ first-in-class inhalation therapeutic RCS-21. 15.11.23 RNATICS announces distinguished Advisory Board Prestigious advisory board with highly experienced members in the nucleic acid therapeutics field will be instrumental in advancing RNATICS' innovative therapies to improve human health. 8.08.23 Underlying science of RNATICS’ technology published in Nature Communications First-in-class mechanism to efficiently target RNA therapeutics to alveolar macrophages and its therapeutic potential described. Load More ... 14.09.22 RNATICS receives prestigious Pharma Trend Image & Innovation Award 2022 for novel RNA therapeutic against COVID-19 RNATICS awarded for breakthrough innovation in RNA therapeutics for its lead programme RCS-21. 9.05.22 RNATICS technology wins Innovationspreis 2022 of BIO Deutschland RNATICS technology selected as one of three outstanding technologies in Germany in 2022. 17.03.22 RNATICS featured in national newspaper rnatics has been covered in the national newspaper Süddeutsche Zeitung as one of three biotech start-ups in Munich working on RNA therapeutics. 13.01.22 RNATICS granted € 7 million for the clinical development of a new COVID-19 drug Federal Ministry of Education and Research funds clinical testing of RCS-21. 13.01.22 Report from the Technical University of Munich on rnatics as one of its most promising startups A spray to protect against lung damage from Covid-19 Downloads Die Beschreibung des Downloads pdf / 13 KB Events Bio-Europe 2024 06.11.24 / Stockholm BIO-Europe is the biggest partnering conference in Europe for the biopharma industry. Learn More LSX Investival Showcase 2024 18.11.24 / London, UK The Investival Showcase connects life science professionals to potential investors. Learn More
8.10.24 2024 Nobel prize in Medicine awarded to microRNA 2024 Nobel prize in Medicine awarded to microRNA - the target of RNATICS’ first-in-class inhalation therapeutic RCS-21.
15.11.23 RNATICS announces distinguished Advisory Board Prestigious advisory board with highly experienced members in the nucleic acid therapeutics field will be instrumental in advancing RNATICS' innovative therapies to improve human health.
8.08.23 Underlying science of RNATICS’ technology published in Nature Communications First-in-class mechanism to efficiently target RNA therapeutics to alveolar macrophages and its therapeutic potential described. Load More ...
14.09.22 RNATICS receives prestigious Pharma Trend Image & Innovation Award 2022 for novel RNA therapeutic against COVID-19 RNATICS awarded for breakthrough innovation in RNA therapeutics for its lead programme RCS-21.
9.05.22 RNATICS technology wins Innovationspreis 2022 of BIO Deutschland RNATICS technology selected as one of three outstanding technologies in Germany in 2022.
17.03.22 RNATICS featured in national newspaper rnatics has been covered in the national newspaper Süddeutsche Zeitung as one of three biotech start-ups in Munich working on RNA therapeutics.
13.01.22 RNATICS granted € 7 million for the clinical development of a new COVID-19 drug Federal Ministry of Education and Research funds clinical testing of RCS-21.
13.01.22 Report from the Technical University of Munich on rnatics as one of its most promising startups A spray to protect against lung damage from Covid-19
